The country accounted for about 4% of the Asia-Pacific market in 2024.
Japan’s mycobacterium tuberculosis (TB) tests market is expected to expand at a compound annual growth rate of 4% until 2036, according to GlobalData.
One notable development is the recent $4.5m investment from Japan’s Global Health Innovative Technology Fund to support efforts to develop a compact, ultrasensitive, and non-invasive TB diagnostic platform using advanced biomarker technology.
The multinational collaboration between Fluxus Inc., Fujirebio Inc., and Heidelberg University Hospital aims to develop a highly sensitive, urine-based assay for detecting a key TB biomarker, integrated into a portable point-of-care system
Japan accounted for about 4% of the Asia-Pacific market in 2024, attributed to diagnosis and treatment delays, associated with limited awareness amongst patients and physicians, which hinder timely testing.
“Diagnosing TB remains a challenge due to limited accessibility, suboptimal sensitivity, and delays in results, particularly among children and patients unable to provide sputum samples,” said Divya Soni, Medical Devices Analyst at GlobalData.
“As the world moves toward TB elimination, the development of accessible, sensitive, and field-ready diagnostic tools is more urgent than ever,” Soni added.
